#sagerstrong | PROCEEDS WILL GO DIRECTLY TO FUND CLINICAL TRIALS AND CANCER RESEARCH FOR LEUKEMIA AND OTHER BLOOD CANCERS.

RESEARCH AT MD ANDERSON HOUSTON, TX

Philanthropic support is pivotal in moving the needle and we are grateful for your interest in Dr. Pemmaraju’s AML research.  As I mentioned, Dr. Pemmaraju is currently engaged in two clinical trials with a third opening next month.  Below is a description of each.

RESEARCH AT MD ANDERSON HOUSTON, TX Philanthropic support is pivotal in moving the needle and we are grateful for your interest in Dr. Pemmaraju’s AML research.  As I mentioned, Dr. Pemmaraju is currently engaged in two clinical trials with a third opening next month.  Below is a description of each.

Patients with AML and BPDCN:

CD123-targeted clinical trial with SL-401. PI: Marina Konopleva, M.D., Co-PI: Naveen Pemmaraju, M.D. We have identified a marker present on many AML blasts called CD123 (or IL3R alpha). This trial is offered to patients with either AML or a rare cancer called Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), which usually expresses high levels of CD123. This trial is open and enrolling currently.

View This Trial

Patients with Myelofibrosis (MF):

Treatment with a Smac Mimetic, LCL-161. PI: Naveen Pemmaraju, M.D., Co-PI: Srdan Verstovsek, M.D., Ph.D. We will treat patients with a very new type of targeted therapy that aims to promote cell death (apoptosis) in cancer cells that overexpress certain proteins that prevent them from dying normally. I will collaborate with a senior scientist, Bing Carter, M.D., to test all patient samples for correlative studies of the markers of cell death. This will help us understand the exact nature of the drug targets and the tumor cells. This trial is enrolling patients.

View This Trial

Patients with Advanced Myeloproliferative Neoplasms (MPNs):

CMML, HES, SM, MF. Treatment with Targeted Therapy. PI: Naveen Pemmaraju, M.D., Co-PI: Srdan Verstovsek, M.D., Ph.D. This clinical trial is slated to open next month. It is for patients with advanced MPNs who have had one prior line of therapy. We will offer them a new therapy targeted at molecules found/expressed on the blast/stem cells of their tumors.

View This Trial